VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
ESTA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
ESTAEstablishment Labs Holdings Inc.
$87.42$2.6B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksESTAFinancials

Establishment Labs Holdings Inc. (ESTA) Financials

10Y historyFree accessUpdated daily

Revenue growth accelerated to 44.7% in 2026Q1, though the company continues to struggle with profitability, reporting a negative operating margin of 10.9%.

ESTA Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16
Sales/Revenue229.58M211.08M166.03M165.15M161.7M126.68M84.68M89.56M61.21M34.68M19.8M
Revenue Growth %34.86%27.14%0.53%2.13%27.64%49.61%-5.46%46.33%76.49%75.15%-
Cost of Goods Sold68.74M64.77M56.5M58.17M55.1M41.28M32.17M34.7M25.09M16.98M9.71M
COGS % of Revenue-30.68%34.03%35.22%34.08%32.58%38%38.75%40.99%48.96%49.01%
Gross Profit160.84M146.31M109.53M106.98M106.59M85.4M52.5M54.86M36.12M17.7M10.1M
Gross Margin %70.06%69.32%65.97%64.78%65.92%67.42%62%61.25%59.01%51.04%50.99%
Gross Profit Growth %-33.58%2.38%0.36%24.81%62.67%-4.3%51.89%104.03%75.34%-
Operating Expenses189.41M185.32M159.51M172M146.25M110.54M80.42M85.8M59.98M37.69M25.93M
OpEx % of Revenue-87.8%96.08%104.15%90.45%87.26%94.97%95.8%98%108.66%130.95%
Selling, General & Admin168.97M165.07M139.81M145.57M125.98M92.23M66.63M70.81M47.3M30.82M23.19M
SG&A % of Revenue-78.2%84.21%88.15%77.91%72.8%78.68%79.06%77.27%88.87%117.11%
Research & Development20.43M20.25M19.71M26.43M20.27M18.32M13.79M14.99M12.69M6.86M2.74M
R&D % of Revenue-9.59%11.87%16%12.53%14.46%16.29%16.74%20.73%19.79%13.84%
Other Operating Expenses00000000000
Operating Income-28.57M-39.01M-49.99M-65.03M-39.66M-25.14M-27.92M-30.94M-23.86M-19.98M-15.83M
Operating Margin %-12.45%-18.48%-30.11%-39.37%-24.53%-19.84%-32.97%-34.55%-38.99%-57.62%-79.96%
Operating Income Growth %-21.96%23.13%-63.97%-57.75%9.94%9.78%-29.66%-19.42%-26.21%-
EBITDA-24.33M-32.77M-42.41M-60.14M-35.49M-21.03M-24.25M-27.64M-21.06M-18.04M-15.24M
EBITDA Margin %-10.6%-15.52%-25.54%-36.42%-21.95%-16.6%-28.64%-30.86%-34.41%-52.03%-76.97%
EBITDA Growth %50.72%22.74%29.48%-69.47%-68.72%13.27%12.26%-31.22%-16.74%-18.39%-
D&A (Non-Cash Add-back)4.98M07.58M4.88M4.17M4.11M3.66M3.3M2.8M1.94M592K
EBIT-25.33M-32.77M-63.8M-63.19M-61.06M-30.65M-28.64M-28.81M-12.07M-24.37M-18.61M
Net Interest Income-26.29M-24.83M-19.35M-14.37M-11.67M-9.04M-9.36M-8.69M-8.8M-10.4M-3.37M
Interest Income199K423K1.48M1.02M87K23K15K4K16K19K44K
Interest Expense26.49M25.26M20.83M15.39M11.76M9.06M9.37M8.7M8.81M10.42M3.41M
Other Income/Expense-22.75M-19.01M-34.64M-13.56M-33.17M-14.57M-10.1M-6.57M2.98M-14.81M-6.19M
Pretax Income-51.32M-58.02M-84.63M-78.58M-72.82M-39.71M-38.02M-37.51M-20.88M-34.79M-22.02M
Pretax Margin %-22.35%-27.49%-50.97%-47.58%-45.04%-31.35%-44.9%-41.88%-34.12%-100.32%-111.23%
Income Tax-7.58M-6.96M-32K-81K2.38M1.43M104K640K215K105K134K
Effective Tax Rate %14.78%11.99%0.04%0.1%-3.28%-3.59%-0.27%-1.71%-1.03%-0.3%-0.61%
Net Income-43.74M-51.06M-84.6M-78.5M-75.21M-41.14M-38.12M-38.15M-21.1M-34.9M-22.16M
Net Margin %-19.05%-24.19%-50.95%-47.53%-46.51%-32.47%-45.02%-42.59%-34.47%-100.62%-111.91%
Net Income Growth %50.92%39.64%-7.76%-4.38%-82.82%-7.92%0.08%-80.82%39.54%-57.48%-
Net Income (Continuing)-43.74M-51.06M-84.6M-78.5M-75.21M-41.14M-38.12M-38.15M-21.1M-34.9M-22.16M
Discontinued Operations00000000000
Minority Interest00000000000
EPS (Diluted)-1.48-1.72-3.00-3.07-3.08-1.72-1.63-1.86-1.22-1.89-1.20
EPS Growth %52.47%42.67%2.28%0.32%-79.07%-5.52%12.37%-52.46%35.45%-57.5%-
EPS (Basic)--1.72-3.00-3.07-3.08-1.72-1.63-1.86-1.22-2.33-1.20
Diluted Shares Outstanding29.62M29.62M28.16M25.6M24.46M23.97M23.32M20.54M17.35M18.49M18.49M
Basic Shares Outstanding29.62M29.62M28.16M25.6M24.46M23.97M23.32M20.54M17.35M14.98M18.49M
Dividend Payout Ratio-----------

Key Metrics

Growth RegimeAccelerating
ProfitabilityNegative
Balance SheetStrained
Cash FlowBurning
Top Statement Risk

US Regulatory Approval Delay

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Scaling Amidst Market Expansion

According to the latest quarterly data, Establishment Labs achieved a 44.7% year-over-year revenue growth in 2026Q1, signaling a robust recovery from the contraction observed in early 2024 and suggesting that international market penetration for the Motiva brand is accelerating despite the absence of US commercial operations.

The recent revenue trajectory indicates that the company is successfully capturing market share in its existing international footprint. Investors should monitor whether this growth rate is sustainable or if it reflects a temporary surge in demand as the company prepares for potential US market entry.

Premium Positioning Supports Gross Margins

As reported in financial statements, the company maintained a gross margin of 70.7% in 2026Q1, which reflects the premium nature of its SmoothSilk technology and suggests that the firm possesses significant pricing power relative to lower-tier medical device manufacturers in the aesthetics space.

The stability of gross margins above 70% indicates that the manufacturing process in Costa Rica is efficient and that the product commands a premium price point. This structural advantage provides a necessary buffer as the company continues to absorb high operating costs associated with its global expansion.

Operating Leverage Remains Elusive

Based on the provided income statement data, operating expenses continue to track closely with gross profit, resulting in a negative operating margin of 10.9% in 2026Q1, which implies that the company has yet to achieve the necessary scale to leverage its fixed SG&A cost base.

The persistent gap between revenue growth and operating profitability suggests that management is prioritizing aggressive market development over immediate bottom-line efficiency. Analysts should investigate whether this spending is tied to non-recurring regulatory milestones or if it represents a structural requirement for maintaining a global sales force.

Sustainability of Growth and Cash

Analysis of the income statement reveals a recurring pattern of net losses, with a 2026Q1 net margin of -22.3%, which warrants further investigation into the company's long-term liquidity and the potential for future equity dilution to fund ongoing operations in the absence of positive cash flow.

The reliance on external capital to bridge the gap between operating losses and growth initiatives creates a binary risk profile for shareholders. If the company fails to reach a cash-flow-positive state before its current reserves are exhausted, the resulting dilution could significantly impair existing equity value.

ESTA — Frequently Asked Questions

Quick answers to the most common questions about buying ESTA stock.

What was Establishment Labs Holdings Inc.'s (ESTA) revenue in 2025?

For fiscal year 2025, Establishment Labs Holdings Inc. (ESTA) reported total revenue of $211.1M. This represents a 966.0% increase compared to $19.8M in 2016.

Is Establishment Labs Holdings Inc. (ESTA) profitable?

Establishment Labs Holdings Inc. (ESTA) reported a net loss of $51.1M for the fiscal year ending 2025.

What is Establishment Labs Holdings Inc.'s operating profit margin?

Establishment Labs Holdings Inc. (ESTA) reported an operating income of $-39.0M, resulting in an operating profit margin of -18.5%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Establishment Labs Holdings Inc.'s gross profit and gross margin?

Establishment Labs Holdings Inc. (ESTA) generated $146.3M in gross profit for the year, representing a gross profit margin of 69.3%. This demonstrates the company's core pricing power and production efficiency.